Abstract
Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and
Original language | English |
---|---|
Pages (from-to) | 2328-2336 |
Number of pages | 9 |
Journal | Diabetologia |
Volume | 52 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2009 |
Keywords
- Blood pressure control
- Cardiovascular disease risk
- Cognitive function
- Glucose control
- Hypoglycaemia
- MMSE
- Mortality
- Type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism